Investigators compared outcomes between patients with stage II/III colon cancer given adjuvant aspirin and those given ...

An NIH-supported clinical trial of pomalidomide in treating hereditary hemorrhagic telangiectasia stopped early due to ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial (1) and cervical cancers (2) who gain clinically meaningful benefit from adding immunotherapy to current standard ...

At the European Association for the Study of Diabetes annual meeting, Novo Nordisk A/S (NYSE:NVO) shared an abstract with ...

A study was conducted to determine the 52-week efficacy and safety of lerodalcibep in patients with cardiovascular disease receiving LDL-C-lowering treatment.

Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared ...

ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured ...

Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo adjusted)Well-tolerated with no treatment-related dose ...

Is the fear of gaining a few pounds preventing you from quitting smoking? You’re not alone, said Dr. Luba Yammine, associate professor of psychiatry at UTHealth Houston.  In fact, a meta-analysis of ...

Bayer presents detailed results from OASIS 3 phase III study of elinzanetant to treat VMS associated with menopause at 2024 TMS meeting: Berlin Thursday, September 12, 2024, 11:00 ...